Circulating Biomarker Results From a Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension
Authors:
- Robin OsterhoutRORobin Osterhout
- Athénaïs BouclyABAthénaïs Boucly
- Raymond L BenzaRBRaymond L Benza
- Richard N ChannickRCRichard N Channick
- Kelly M ChinKCKelly M Chin
- Robert P FrantzRFRobert P Frantz
- Anna R HemnesAHAnna R Hemnes
- Luke S HowardLHLuke S Howard
- Vallerie V MclaughlinVMVallerie V Mclaughlin
- Olivier SitbonOSOlivier Sitbon
- Jean-Luc VachiéryJVJean-Luc Vachiéry
- Roham T ZamanianRZRoham T Zamanian
Open Access
- 8 May 2026
- journal article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (8) , 1832-1837
Abstract
No abstract availableKeywords
Funding Information
- a wholly owned subsidiary of Gossamer Bio, Inc
This publication has 10 references indexed in Scilit:
- Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension StudyAdvances in Therapy, 2025
- Clustering Patients with Pulmonary Hypertension Using the Plasma ProteomeAmerican Journal of Respiratory and Critical Care Medicine, 2025
- Sustained effect of seralutinib on circulating biomarkers: Lessons from the TORREY phase 2 open-label extension studyEuropean Respiratory Journal, 2024
- Digital Spatial Profiling Identifies Distinct Molecular Signatures of Vascular Lesions in Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2024
- Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trialThe Lancet Respiratory Medicine, 2024
- TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation, and Fibrosis Improve With Treatment2024
- Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial HypertensionInternational Journal of Molecular Sciences, 2023
- Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertensionEuropean Respiratory Journal, 2022
- Circulating Markers of Inflammation and Angiogenesis and Clinical Outcomes Across Subtypes of Pulmonary Arterial HypertensionThe Journal of Heart and Lung Transplantation, 2022
- Circulating Angiogenic Modulatory Factors Predict Survival and Functional Class in Pulmonary Arterial HypertensionPulmonary Circulation, 2013